Interleukin-2 as maintenance therapy for children and adults with acute myeloid leukaemia in first complete remission (Q24187927)

2

0 references

Jin-Qiu Yuan

3

0 references

Zu-Yao Yang

4

0 references

Ya-Fang Huang

5

0 references

Qian-Ling YE

6

0 references

Xin-Yin Wu

7

0 references

Xue-Feng Hu

8

0 references

Zhi-Min Zhai

9

0 references

Jin-Ling Tang

Cochrane Database of Systematic Reviews

10

0 references

publication date

6 November 2015

0 references

published in

0 references

cites work

Low-dose interleukin-2 immunotherapy does not improve outcome of patients age 60 years and older with acute myeloid leukemia in first complete remission: Cancer and Leukemia Group B Study 9720.

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD010248.PUB2

Recombinant interleukin-2 in patients aged younger than 60 years with acute myeloid leukemia in first complete remission: results from Cancer and Leukemia Group B 19808

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD010248.PUB2

P-glycoprotein inhibition using valspodar (PSC-833) does not improve outcomes for patients younger than age 60 years with newly diagnosed acute myeloid leukemia: Cancer and Leukemia Group B study 19808

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD010248.PUB2

Outcomes in CCG-2961, a children's oncology group phase 3 trial for untreated pediatric acute myeloid leukemia: a report from the children's oncology group

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD010248.PUB2

Soluble interleukin-2 receptor α activation in a Children's Oncology Group randomized trial of interleukin-2 therapy for pediatric acute myeloid leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD010248.PUB2

Randomized study of intensified anthracycline doses for induction and recombinant interleukin-2 for maintenance in patients with acute myeloid leukemia age 50 to 70 years: results of the ALFA-9801 study

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD010248.PUB2

Feasibility, toxicity, and biologic response of interleukin-2 after consolidation chemotherapy for acute myelogenous leukemia: a report from the Children's Cancer Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD010248.PUB2

Low dose interleukin-2 following intensification therapy with high dose cytarabine for acute myelogenous leukemia in first complete remission

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD010248.PUB2

Ethnicity and survival in childhood acute myeloid leukemia: a report from the Children's Oncology Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD010248.PUB2

Age and acute myeloid leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD010248.PUB2

Proposals for the Classification of the Acute Leukaemias French-American-British (FAB) Co-operative Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD010248.PUB2

Improved leukemia-free survival after postconsolidation immunotherapy with histamine dihydrochloride and interleukin-2 in acute myeloid leukemia: results of a randomized phase 3 trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD010248.PUB2

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD010248.PUB2

Individual patient data meta-analysis of randomized trials evaluating IL-2 monotherapy as remission maintenance therapy in acute myeloid leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD010248.PUB2

Selective modulation of human natural killer cells in vivo after prolonged infusion of low dose recombinant interleukin 2.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD010248.PUB2

Cytogenetics and age are major determinants of outcome in intensively treated acute myeloid leukemia patients older than 60 years: results from AMLSG trial AML HD98-B.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD010248.PUB2

World Health Organization classification of neoplastic diseases of the hematopoietic and lymphoid tissues: report of the Clinical Advisory Committee meeting-Airlie House, Virginia, November 1997.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD010248.PUB2

Defective T-helper cell function after T-cell-depleting therapy affecting naive and memory populations.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD010248.PUB2

Age and acute myeloid leukemia: real world data on decision to treat and outcomes from the Swedish Acute Leukemia Registry

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD010248.PUB2

Maintenance therapy in acute myeloid leukemia revisited: will new agents rekindle an old interest?

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD010248.PUB2

21 January 2018

Acute myeloid leukemia

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD010248.PUB2

A phase II study of interleukin-2 in 49 patients with relapsed or refractory acute leukemia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD010248.PUB2

Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD010248.PUB2

Extracting summary statistics to perform meta-analyses of the published literature for survival endpoints

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD010248.PUB2

Post-consolidation immunotherapy with histamine dihydrochloride and interleukin-2 in AML.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD010248.PUB2

Interleukin-2 after autologous stem-cell transplantation for adult patients with acute myeloid leukemia in first complete remission

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD010248.PUB2

Histamine dihydrochloride and low-dose interleukin-2 as post-consolidation immunotherapy in acute myeloid leukemia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD010248.PUB2

Practical methods for incorporating summary time-to-event data into meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD010248.PUB2

The 2008 revision of the World Health Organization (WHO) classification of myeloid neoplasms and acute leukemia: rationale and important changes

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD010248.PUB2

Prognostic factor analysis of the survival of elderly patients with AML in the MRC AML11 and LRF AML14 trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD010248.PUB2

Interleukin-2 as maintenance therapy for children and adults with acute myeloid leukaemia in first complete remission

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD010248.PUB2

Ethnicity and prognosis in acute myeloid leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD010248.PUB2

inferred from DOI database lookup

7 January 2021

based on heuristic

Intensive chemotherapy with idarubicin, ara-C, etoposide, and m-AMSA followed by immunotherapy with interleukin-2 for myelodysplastic syndromes and high-risk Acute Myeloid Leukemia (AML)

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD010248.PUB2

inferred from DOI database lookup

7 January 2021

based on heuristic

Remission maintenance therapy with histamine and interleukin-2 in acute myelogenous leukaemia

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD010248.PUB2